KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $337.3 million.

  • CRISPR Therapeutics AG's Total Non-Current Liabilities rose 1004.14% to $337.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $337.3 million, marking a year-over-year increase of 1004.14%. This contributed to the annual value of $337.3 million for FY2025, which is 1004.14% up from last year.
  • CRISPR Therapeutics AG's Total Non-Current Liabilities amounted to $337.3 million in Q4 2025, which was up 1004.14% from $324.0 million recorded in Q3 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's Total Non-Current Liabilities peaked at $394.1 million during Q3 2022, and registered a low of $144.3 million during Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $345.4 million (2021), whereas its average is $332.3 million.
  • As far as peak fluctuations go, CRISPR Therapeutics AG's Total Non-Current Liabilities skyrocketed by 14531.38% in 2022, and later plummeted by 1158.26% in 2025.
  • Quarter analysis of 5 years shows CRISPR Therapeutics AG's Total Non-Current Liabilities stood at $345.1 million in 2021, then increased by 4.79% to $361.6 million in 2022, then decreased by 4.37% to $345.8 million in 2023, then dropped by 11.36% to $306.5 million in 2024, then grew by 10.04% to $337.3 million in 2025.
  • Its Total Non-Current Liabilities stands at $337.3 million for Q4 2025, versus $324.0 million for Q3 2025 and $314.1 million for Q2 2025.